EGFR inhibitors in NSCLC and the role of biomarkers for selection of patients [electronic resource] / Fred R. Hirsch.
Material type:![Film](/opac-tmpl/lib/famfamfam/VM.png)
Animated audio-visual presentation with synchronized narration.
Title from title frames.
Contents: USAEGFR TKIs in 2nd /3rd line therapy -- Phase II activity of EGFR TKIs in unselected NSCLC -- BR.21 study design and overall survival -- Forest plot of survival by subsets -- Is there a survival advantage for male smokers with squamous-cell carcinoma? -- Trials comparing Gefitinib to Docetaxel -- SIGN trial -- RECIST study -- INTEREST study -- EGFR inhibitors in first line therapy -- Randomized Trials of CT+/- active targeted Rx -- Maintenance of Gefitinib WJTOG 0203 -- Cetuximab in NSCLC -- EGFR interacting molecules.
Access restricted to subscribers.
Mode of access: World Wide Web.